Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTENSIFY: Early-Intensified Pharmacological Treatment for Schizophrenia, MDD, and Bipolar Depression
NCT05603104Phase 3Recruiting
- Start
- Apr 2025
- Primary completion
- Jun 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of clozapine, esketamine and ketamine in schizophrenia, major depressive disorder (MDD) and bipolar disorder (BD) (6 arms). Primary endpoint: Change in symptom severity at 6 weeks. Started Apr 2025; status: recruiting.
02
Drugs
clozapineesketamineketamine
03
Conditions
schizophreniamajor depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT05603104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05603104.